Recordati Industria Chimica e Farmaceutica S.p.A. (RCDTF)
USD 56.04
(14.37%)
USD 56.04
(14.37%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 4.2 Billion EUR | 5.23% |
| 2022 | 3.99 Billion EUR | 41.99% |
| 2021 | 2.81 Billion EUR | 3.86% |
| 2020 | 2.71 Billion EUR | -3.46% |
| 2019 | 2.8 Billion EUR | 29.84% |
| 2018 | 2.16 Billion EUR | 5.2% |
| 2017 | 2.05 Billion EUR | 31.76% |
| 2016 | 1.56 Billion EUR | 6.25% |
| 2015 | 1.46 Billion EUR | 6.81% |
| 2014 | 1.37 Billion EUR | 7.12% |
| 2013 | 1.28 Billion EUR | 18.12% |
| 2012 | 1.08 Billion EUR | 11.19% |
| 2011 | 977.46 Million EUR | 8.48% |
| 2010 | 901.07 Million EUR | 9.42% |
| 2009 | 823.47 Million EUR | 0.92% |
| 2008 | 815.94 Million EUR | 8.12% |
| 2007 | 754.69 Million EUR | 12.5% |
| 2006 | 670.84 Million EUR | 3.62% |
| 2005 | 647.39 Million EUR | 11.82% |
| 2004 | 578.94 Million EUR | 14.6% |
| 2003 | 505.2 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | 4.28 Billion EUR | 1.74% |
| 2024 Q2 | 4.2 Billion EUR | -1.88% |
| 2023 FY | 4.2 Billion EUR | 5.23% |
| 2023 Q1 | 3.98 Billion EUR | -0.42% |
| 2023 Q2 | 4.2 Billion EUR | 5.68% |
| 2023 Q3 | 4.23 Billion EUR | 0.55% |
| 2023 Q4 | 4.2 Billion EUR | -0.55% |
| 2022 Q3 | 3.97 Billion EUR | -0.16% |
| 2022 FY | 3.99 Billion EUR | 41.99% |
| 2022 Q4 | 3.99 Billion EUR | 0.53% |
| 2022 Q1 | 3.64 Billion EUR | 29.36% |
| 2022 Q2 | 3.98 Billion EUR | 9.36% |
| 2021 Q3 | 2.92 Billion EUR | 1.86% |
| 2021 Q4 | 2.81 Billion EUR | -3.87% |
| 2021 FY | 2.81 Billion EUR | 3.86% |
| 2021 Q1 | 2.83 Billion EUR | 4.64% |
| 2021 Q2 | 2.87 Billion EUR | 1.36% |
| 2020 Q3 | 2.81 Billion EUR | 0.01% |
| 2020 Q4 | 2.71 Billion EUR | -3.5% |
| 2020 FY | 2.71 Billion EUR | -3.46% |
| 2020 Q1 | 2.82 Billion EUR | 0.49% |
| 2020 Q2 | 2.8 Billion EUR | -0.46% |
| 2019 FY | 2.8 Billion EUR | 29.84% |
| 2019 Q3 | 2.68 Billion EUR | 23.64% |
| 2019 Q2 | 2.16 Billion EUR | -2.37% |
| 2019 Q1 | 2.22 Billion EUR | 2.7% |
| 2019 Q4 | 2.8 Billion EUR | 4.73% |
| 2018 FY | 2.16 Billion EUR | 5.2% |
| 2018 Q3 | 2.06 Billion EUR | 2.21% |
| 2018 Q4 | 2.16 Billion EUR | 5.02% |
| 2018 Q2 | 2.01 Billion EUR | 2.18% |
| 2018 Q1 | 1.97 Billion EUR | -4.09% |
| 2017 Q2 | 1.76 Billion EUR | 5.8% |
| 2017 FY | 2.05 Billion EUR | 31.76% |
| 2017 Q4 | 2.05 Billion EUR | 2.07% |
| 2017 Q3 | 2.01 Billion EUR | 13.83% |
| 2017 Q1 | 1.67 Billion EUR | 7.18% |
| 2016 FY | 1.56 Billion EUR | 6.25% |
| 2016 Q4 | 1.56 Billion EUR | -3.53% |
| 2016 Q3 | 1.61 Billion EUR | 3.26% |
| 2016 Q2 | 1.56 Billion EUR | 1.89% |
| 2016 Q1 | 1.53 Billion EUR | 4.69% |
| 2015 Q2 | 1.48 Billion EUR | 0.56% |
| 2015 Q4 | 1.46 Billion EUR | -1.96% |
| 2015 Q3 | 1.49 Billion EUR | 0.99% |
| 2015 Q1 | 1.47 Billion EUR | 7.27% |
| 2015 FY | 1.46 Billion EUR | 6.81% |
| 2014 Q1 | 1.34 Billion EUR | 5.06% |
| 2014 FY | 1.37 Billion EUR | 7.12% |
| 2014 Q4 | 1.37 Billion EUR | -6.25% |
| 2014 Q3 | 1.46 Billion EUR | 8.51% |
| 2014 Q2 | 1.35 Billion EUR | 0.22% |
| 2013 Q4 | 1.28 Billion EUR | 5.36% |
| 2013 Q2 | 1.18 Billion EUR | -2.11% |
| 2013 Q1 | 1.2 Billion EUR | 11.18% |
| 2013 FY | 1.28 Billion EUR | 18.12% |
| 2013 Q3 | 1.21 Billion EUR | 3.01% |
| 2012 Q1 | 1.02 Billion EUR | 5.24% |
| 2012 Q2 | 1.01 Billion EUR | -0.97% |
| 2012 Q3 | 1.05 Billion EUR | 3.59% |
| 2012 FY | 1.08 Billion EUR | 11.19% |
| 2012 Q4 | 1.08 Billion EUR | 2.99% |
| 2011 Q3 | 1.03 Billion EUR | 6.4% |
| 2011 Q4 | 977.46 Million EUR | -5.33% |
| 2011 Q1 | 987.65 Million EUR | 9.61% |
| 2011 Q2 | 970.34 Million EUR | -1.75% |
| 2011 FY | 977.46 Million EUR | 8.48% |
| 2010 Q1 | 839.97 Million EUR | 2.0% |
| 2010 FY | 901.07 Million EUR | 9.42% |
| 2010 Q2 | 823.03 Million EUR | -2.02% |
| 2010 Q3 | 842.43 Million EUR | 2.36% |
| 2010 Q4 | 901.07 Million EUR | 6.96% |
| 2009 Q4 | 823.47 Million EUR | 0.0% |
| 2009 FY | 823.47 Million EUR | 0.92% |
| 2008 FY | 815.94 Million EUR | 8.12% |
| 2007 FY | 754.69 Million EUR | 12.5% |
| 2006 FY | 670.84 Million EUR | 3.62% |
| 2005 FY | 647.39 Million EUR | 11.82% |
| 2004 FY | 578.94 Million EUR | 14.6% |
| 2003 FY | 505.2 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| AstraZeneca PLC | 100.97 Billion USD | 95.833% |
| Bristol-Myers Squibb Company PFD CONV 2 | 95.15 Billion USD | 95.578% |
| CSPC Pharmaceutical Group Limited | 6.52 Billion USD | 35.498% |
| Clarus Therapeutics Holdings, Inc. | 51.7 Million USD | -8038.259% |
| Novartis AG | 99.94 Billion USD | 95.79% |
| PT Kalbe Farma Tbk. | 1.75 Billion USD | -139.269% |